Sleep Apnea

Apnimed has secured $300 million through two financing deals as it prepares to submit a new drug application to the FDA for AD109, a once-nightly pill that reduced breathing interruptions by up to 56% in clinical trials.

A meta-analysis of more than 13,000 adults found that people with obstructive sleep apnea are 85% more likely to develop sarcopenia — and CT imaging studies show their muscles may be infiltrated with fat even when they appear normal in size.

A study of 3,159 people monitored over multiple nights found that high night-to-night variability in sleep apnea severity independently increased the odds of major cardiovascular events by 34% — suggesting that standard one-night sleep tests may underestimate risk for a hidden group of patients.

The FDA granted premarket approval to LivaNova's aura6000, the first hypoglossal nerve stimulation device for sleep apnea that does not exclude patients with complete concentric collapse of the airway.

A Vanderbilt and Harvard study found that up to 69% of former NFL players may have sleep apnea — most of it undiagnosed — and that untreated cases are strongly linked to the cognitive and psychiatric symptoms often attributed to concussion-related brain damage.

A study of nearly 2.9 million people in the UK found that those with obstructive sleep apnea had a 71% higher risk of cardiovascular events or death compared to matched controls — and elevated rates of obesity, diabetes, and mental health conditions.

A Mount Sinai study published in Nature Communications Medicine introduces a machine learning model that can predict whether CPAP therapy will reduce or increase cardiovascular risk for individual sleep apnea patients — a first step toward personalized treatment decisions.

A review in Respirology finds that four distinct biological mechanisms drive obstructive sleep apnea in different patients, and that matching treatments to each mechanism could transform care — especially for the millions who abandon CPAP.

A Yale study of nearly 1 million U.S. veterans found that people with both insomnia and obstructive sleep apnea face nearly four times the risk of cardiovascular disease compared to those without either condition.

A large European clinical trial found that sulthiame, an existing epilepsy medication, reduced breathing interruptions during sleep by up to 47% in patients with moderate to severe obstructive sleep apnea, raising hopes for a pharmaceutical alternative to CPAP therapy.

Pharmaceutical company Apnimed plans to file for FDA approval of AD109 in early 2026 after the drug met its primary endpoint in a second Phase 3 trial, potentially offering relief to patients who struggle with CPAP therapy.

UC Davis Medical Center became the first hospital in Northern California to implant the Genio system, an FDA-approved device that stimulates nerves to keep airways open during sleep without requiring an internal battery.

SleepRes received FDA 510(k) clearance for its Kricket PAP device, which uses adaptive pressure technology to synchronize with natural breathing patterns and potentially improve patient comfort.